Publications
Search our bibliography using the filters on the right-hand side.
Displaying 301 through 350 of 10192 publications.
Skip to main content
Fleming AD, Mellor J, McGurnaghan SJ, Blackbourn LAK, Goatman KA, Styles C, Storkey AJ, McKeigue PM, Colhoun HM. Deep learning detection of diabetic retinopathy in Scotland's diabetic eye screening programme. Br J Ophthalmol. 2024 Jun 20;108(7):984-8. doi: 10.1136/bjo-2023-323395
Perreault S, Hukin J, Erker C, Silayuv EB, Hamilton MA, Kim Y, Jimenez MI, Candrilli SD. Treatment patterns and healthcare resource utilization of pediatric patients with neurofibromatosis type 1 and unresectable plexiform neurofibroma in Canada. Poster presented at the 2024 Global NF Conference; June 20, 2024. Brussels, Belgium.
Mumma JM, Weaver BW, Morgan JS, Ghassemian G, Gannon PR, Burke KB, Berryhill BA, MacKay RE, Lee L, Kraft CS. Connecting pathogen transmission and healthcare worker cognition: a cognitive task analysis of infection prevention and control practices during simulated patient care. BMJ Qual Saf. 2024 Jun 19;33(7):419-31. doi: 10.1136/bmjqs-2023-016230
Janssen E, Vass C, Levitan B, Hauber B, Bent R, King-Kallimanis B. Effective patient engagement in patient experience data: practical insights from case studies in hard-to-reach populations. Presented at the Drug Information Association (DIA) 2024 Global Annual Meeting; June 18, 2024. San Diego, CA.
Passamonti F, Parikh RC, Korgaonkar S, Chevli M, Yucel A, Rombi J, Zissler D, Davis KL, Slaff S. Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with myelofibrosis treated with fedratinib. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Campelo MD, Yucel A, Goyal RK, Glassberg MB, Esterberg L, Rombi J, Davis KL, Jimenez M, Miteva D, Germing U. Luspatercept utilization patterns in lower-risk myelodysplastic syndrome (LR-MDS): findings from a multinational medical record review study. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Tilman Steinmetz H, Ertel F, Brinkmann B, Houghton K, Nham T, Flossmann C. Treatment goals and decision-making criteria for second- and third-line therapy for multiple myeloma in Germany. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Schuh AC. Real-World treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia in Canada. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.
Ridley M, Strauss RP, Drake AF, Miller MQ. Narrative study of resilience in facial paralysis: Similarities and differences in the resilience profiles and psychosocial responses of patients with congenital and acquired types. Presented at the Appearance Matters 10 Conference (UWE Bristol); June 11, 2024. Bristol, UK.
Goyal RK, Candrilli SD, Abughosh S, Chen H, Holmes HM, Johnson ML. Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer. Cancers. 2024 Jun 7;16(12):2168. doi: 10.3390/cancers16122168
Mogle J, DeMeo N, Almeida D, Darling A, Greaney J. Measurement bias in daily reports of memory lapses: is reporting influenced by study design? Poster presented at the Society for Ambulatory Assessment 2024; June 3, 2024. Ann Arbor, MI.
Arig D, Baga K, DeMeo NN, Mogle JA. Physical activity measurement reactivity in an at-risk group: coordinated analysis across three studies. Poster presented at the Society for Ambulatory Assessment (SSA) 2024; June 3, 2024. Ann Arbor, MI.
Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K. Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S77. doi: 10.1016/j.jval.2024.03.405
Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Sweeney C, Marshall GS. United States physicians' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024 Jun;74(6):1131-8. doi: 10.1016/j.jadohealth.2023.11.394
La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S138. doi: 10.1016/j.jval.2024.03.738
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.
Gildea L, Arvin-Berod C, Heyes A, Heyerick A, Urdaniz E, Vainilovich Y, Trainor L, Densmore D. Evidence gap analysis of the burden of illness and treatment of thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S35. doi: 10.1016/j.jval.2024.03.184
Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D. Preferences for a combination influenza and COVID-19 vaccine: results from a threshold technique study with consumers in the United Kingdom. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S329. doi: 10.1016/j.jval.2024.03.2055
Poulos C, McMichael A, Kent C, Rudin D, Buck P, Ghaswalla P, Mehta D. Healthcare provider preferences for attributes of influenza vaccines in the United States: results from a discrete-choice experiment study. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S338. doi: 10.1016/j.jval.2024.03.2106
Dong OM, Herring W, Chopra P, Elpers B, Johannesen K. A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S148. doi: 10.1016/j.jval.2024.03.2259
Copley-Merriman K, Miller-Wilson LA, Costello J, Schwinn J, Edwards Y. Evidence gap analysis of the burden of illness and treatment of myasthenia gravis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S384-5. doi: 10.1016/j.jval.2024.03.1792
Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236
Graham CN, Erbe AW. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Jain M, Girardi A, Ridley M, Rudell K, Gold A. Impact of caring for persons with schizophrenia: review of burden assessment measures. Poster presented at the ISPOR 2024; May 5, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S34. doi: 10.1016/j.jval.2024.03.181
Martin S, Kosa K, Podgrabinska S, Garg A, Oral EA, Yildirim Simsir I, Brown RJ, Ozen S, Pagovich O, Srinivasan D, Sanchez RJ. Qualitative interviews describing the patient experience of individuals with generalized lipodystrophy enrolled in a clinical trial of mibavademab. Poster presented at the Endocrine Society (ENDO) 2024; June 1, 2024. Boston, MA.
Masaquel C, Miller-Wilson LA, D'Souza V, Schwinn J, Mina-Osorio P. Evidence gap analysis of the burden of disease in thyroid eye disease. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S389. doi: 10.1016/j.jval.2024.03.2461
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564
Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554
Colacci M, Raissi A, Ray P, Sholzberg M, Rothman KJ, Fralick M. Randomized controlled trials of switching to a new medication vs continuing a chronic medication may underestimate the risk of adverse events in those continuing because of asymmetric depletion of susceptibles. J Clin Epidemiol. 2024 Jun;170:111336. doi: 10.1016/j.jclinepi.2024.111336
Yande S, Johnson ML, Aparasu RR, Toale K, Wanat M. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins in cancer associated thrombosis. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S179. doi: 10.1016/j.jval.2024.03.969
Korgaonkar S, Bentley J, Holmes E, Barnard M, Ramachandran S, Chang Y, Yang Y. Measurement of health insurance literacy and identification of its correlates among working-age cancer survivors in the US. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S345. doi: 10.1016/j.jval.2024.03.2143
Girardi A, Ridley M, Suminski N, Gold A, Rudell K. Saturation reporting in COA development and validation studies: a scoping overview. Poster presented at the ISPOR 2024; May 5, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S54. doi: 10.1016/j.jval.2024.03.2199
Khan AM, Lin P, Kamdar N, Mahmoudi E, Latham-Mintus K, Kobayashi L, Clarke P. Location matters: the role of the neighborhood environment for incident cardiometabolic disease in adults aging with physical disability. Am J Health Promot. 2024 Jun;38(5):633-40. doi: 10.1177/08901171241228017
Bonner C, Pilar M, Jacobs S, Samsell B, Hollis K. Optimizing drug value and access using implementation science. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S318. doi: 10.1016/j.jval.2024.03.2000
O'Brien P, Campbell K, Anderson SJ, Cornic L, Davis A, Schroeder M. Cost-effectiveness of every two month Cabotegravir Long-Acting (CAB-LA) for Pre-exposure Prophylaxis (PrEP) compared with daily oral Tenofovir Disoproxil Fumarate (TDF)/ emtricitabine (FTC) as PrEP to prevent HIV-1 UK. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S109. doi: 10.1016/j.jval.2024.03.580
Petit I, Eliasson L, Romero B, Patel C, Di Rosa A, Quinn J. Exploring the content and psychometric validity of clinical outcome assessments in renal cell carcinoma versus the patient reported symptoms and impacts. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S309. doi: 10.1016/j.jval.2024.03.1955
Roth CL, Shoemaker AH, Ervin C, Norcross L, Fehnel S, Huber C, Scimia C, Abuzzahab MJ. Patient- and caregiver-reported experiences of hunger, weight, and energy in acquired yypothalamic obesity before and during setmelanotide treatment. Poster presented at the Endocrine Society (ENDO) 2024; June 1, 2024. Boston, MA.
Gaudiani L, Sikirica S, Hardin MB, Ervin CM, Goss DS, Kosa KM, Gopinathan S. Patient-reported burden of disease in diabetic peripheral neuropathic pain: learnings from in-depth patient interviews, sub-study of RELIEF-DPN 1. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):484.
Schapiro D, Perez-Nieves M, Vass CM, Ling Poon J, Gelsey FT, Pierce A, Mansfield C. Preferences of people with type 1 diabetes for features of weekly insulin. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):831. doi: 10.2337/db24-831-P
Gelsey F, Perez-Nieves M, Vass CM, Ling Poon J, Schapiro D, Pierce A, Mansfield C. Preferences of people with type 2 diabetes for features of weekly insulin. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):832. doi: 10.2337/db24-832-P
Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).
Miles L, Mauskopf J. Enhancing the value and usefulness of data extracted from an economic systematic literature review. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S407. doi: 10.1016/j.jval.2024.03.1916
Herring WL, Wittrup-Jensen V, Fox L. Value assessment of emerging treatments for nonalcoholic steatohepatitis: lessons from Institute for Clinical and Economic Review evaluations. Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S76. doi: 10.1016/j.jval.2024.03.403